Christiansen Kaare, Bjerring Peter, Troilius Agneta
Molholm Research, 7100 Vejle, Denmark.
Lasers Surg Med. 2007 Apr;39(4):302-10. doi: 10.1002/lsm.20488.
Photodynamic therapy using 20% 5 aminolevulinic acid (5-ALA) has recently been introduced as a new tool in optical skin rejuvenation. The primary objective of this study was to optimize incubation time, the topical delivery mechanism (vehicle) and the concentration of 5-ALA by detecting the dynamic changes of normal skin after 5-ALA application. The secondary objective was to develop a treatment regime which minimizes post-treatment photosensitivity.
STUDY DESIGN/MATERIALS AND METHODS: Skin fluorescence distribution patterns after topical application of low concentrations of 5-ALA (0.5% and 1% preparations encapsulated in liposomes), were investigated. Twenty percent 5-ALA in moisturizing cream was used as a control. Ten healthy volunteers participated, and skin fluorescence was documented by fluorescent photography. The fluorescent intensity was measured in % of maximum obtained fluorescence after 3 hours 5-ALA application.
Skin fluorescence intensity after topical application of 0.5% and 1% non-occluded liposome-encapsulated 5-ALA application was heterogeneous distributed and reached saturation level after approximate 2 hours. The maximal fluorescence for 0.5% and 1% 5-ALA treated areas was 4.2% (SD: 3.5%) and 2.4% (SD: 2%), respectively, and this difference was statistically significant (P = 0.036). The fluorescence decayed linearly shortly (within 15 minutes) after end of application and was back to baseline within 8 hours. In contrast, the fluorescence of areas treated more than 1 hour with 20% 5-ALA was very uniform and a linear relationship (r2 = 0.998) to the incubation time (0-3 hours) was registered. Furthermore, fluorescence intensity (15.2-57.9%) continued to increase after the end of 5-ALA application. The maximum fluorescence reach a level of 1.6-9 times the fluorescence measured by end of the 5-ALA application and occurred 8:13 hours (SD: 0:49 hours) after the end of 20% 5-ALA application. The average skin surface fluorescence induced by the liposome-encapsulated 0.5% 5-ALA applied for longer than 2 hours, was found to be statistically equal (P = 0.47) to the average measured skin surface fluorescence (4.2%) obtained after 30 minutes exposure to 20% 5-ALA cream (4.3%).
Changing the 5-ALA vehicle from a moisturizing cream to liposome encapsulation, the 5-ALA concentration can be lowered by a factor of 40, and still induce the same skin fluorescence and at the same time eliminates the need for occlusion. The low post-treatment fluorescence also suggests a significantly reduced risk of post-treatment phototoxicity.
使用20%的5-氨基乙酰丙酸(5-ALA)进行光动力疗法最近已被引入作为光学嫩肤的一种新工具。本研究的主要目的是通过检测5-ALA应用后正常皮肤的动态变化来优化孵育时间、局部给药机制(载体)和5-ALA的浓度。次要目的是制定一种将治疗后光敏性降至最低的治疗方案。
研究设计/材料与方法:研究了局部应用低浓度5-ALA(包裹在脂质体中的0.5%和1%制剂)后的皮肤荧光分布模式。以保湿霜中的20% 5-ALA作为对照。10名健康志愿者参与,通过荧光摄影记录皮肤荧光。荧光强度以5-ALA应用3小时后获得的最大荧光的百分比来测量。
局部应用0.5%和1%非封闭脂质体包裹的5-ALA后,皮肤荧光强度分布不均,约2小时后达到饱和水平。0.5%和1% 5-ALA治疗区域的最大荧光分别为4.2%(标准差:3.5%)和2.4%(标准差:2%),且这种差异具有统计学意义(P = 0.036)。应用结束后不久(15分钟内)荧光呈线性衰减,并在8小时内恢复到基线水平。相比之下,用20% 5-ALA处理超过1小时的区域的荧光非常均匀,并且与孵育时间(0 - 3小时)呈线性关系(r2 = 0.998)。此外,5-ALA应用结束后荧光强度(15.2 - 57.9%)继续增加。最大荧光达到5-ALA应用结束时测量荧光的1.6 - 9倍水平,并在20% 5-ALA应用结束后8:13小时(标准差:0:49小时)出现。发现应用超过2小时的脂质体包裹的0.5% 5-ALA诱导的平均皮肤表面荧光与暴露于20% 5-ALA乳膏30分钟后获得的平均测量皮肤表面荧光(4.3%)在统计学上相等(P = 0.47)。
将5-ALA的载体从保湿霜改为脂质体包裹,5-ALA浓度可降低40倍,仍能诱导相同的皮肤荧光,同时无需封闭。治疗后低荧光也表明治疗后光毒性风险显著降低。